United States · Bill · HR
H.R. 8877 (117th)
Biologics Competition Act of 2022
Introduced
19 September 2022
Last action
20 September 2022 · Referred
Status
Referred to the Subcommittee on Health.
Sponsors
Rep. Miller-Meeks, Mariannette [R-IA-1], Rep. Murphy, Gregory F. [R-NC-3], Rep. Barragán, Nanette Diaz [D-CA-44], Ann Kuster, Stephanie Bice
Subjects
Healthcare
Source updated
3 January 2025
Summary
Biologics Competition Act of 2022 This bill requires the Food and Drug Administration (FDA) to evaluate (1) the differences between the requirements that apply to interchangeable biologics and the requirements that apply to therapeutically equivalent ratings for generic drugs, and (2) the effects of these differences on the approval of interchangeable biologics. The FDA must update the Purple Book with changes that better align the ways these requirements are communicated while still maintaining each distinct approval pathway. The Purple Book is an FDA publication that lists approved biological products, including biosimilars and interchangeable biologics. Interchangeable biologics are biologics that may be substituted for the original product without consulting the prescriber, similar to how generic drugs may be substituted for brand-name drugs based on therapeutic equivalence.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
19 September 2022
Introduced
Referred to the House Committee on Energy and Commerce.
Source: IntroReferral
19 September 2022
Introduced
Introduced in House
Source: IntroReferral
19 September 2022
Introduced
Introduced in House
Source: IntroReferral
20 September 2022
Referred
Referred to the Subcommittee on Health.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 19 September 2022 · Official file
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 19 September 2022
Introduced in House (PDF)
Introduced in House · EN · 19 September 2022
Introduced in House
summary · EN · 19 September 2022
Sponsors
- Rep. Miller-Meeks, Mariannette [R-IA-1] · R · Sponsor
- Rep. Murphy, Gregory F. [R-NC-3] · R · Sponsor
- Rep. Barragán, Nanette Diaz [D-CA-44] · D · Sponsor
- Ann Kuster · D · Sponsor
- Stephanie Bice · R · Cosponsor
- · hsif00 · Standing
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/8877
- Open data entity: https://api.congress.gov/v3/bill/117/hr/8877
- us · 117-hr-8877 · source updated 3 January 2025